Dr. Vivian Doelling has been appointed vice president of Animal Health at SCYNEXIS, Inc. Dr. Doelling has more than 20 years of experience in the animal health field in the creation and management of biological R&D operations for therapeutic proteins and vaccines for human and animal use.
 
Previously, Dr. Doelling worked as a consultant for the biotechnology and animal health industries, focusing on product development, technology assessment, IP portfolio management, licensing, commercialization and strategic planning. Prior to this, she served as vice president of R&D for Embrex, Inc. and director of R&D after Pfizer Animal Health acquired Embrex.
 
“Vivian’s extensive background in animal health will play a key role in the development and growth of our animal health business, expanding our research beyond parasitology,” said Dr. Yves Ribeill, SCYNEXIS’ president and chief executive officer. “Her contributions to SCYNEXIS will be important as we continue to expand our offerings to our animal health partners and to identify new drug candidates, such as SCY-641 for the treatment of canine keratoconjunctivitis sicca.”